<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="URINARY ALKALIZERS" code="B05-001" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quinidine and risk of overdose (decrease of the renal excretion of the quinidine by alkalinizing of the urine).</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring, EKG, and possibly testing of the quinidinemia; if there is reason for it, adjustment of the dosage during the alkalinizing treatment and after it is stopped.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ALISKIREN" rxcui="325646">
<ATC code="C09XA02" />
<ATC code="C09DX02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of aliskiren and increase of the risk of its undesirable effects.</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="COBICISTAT" rxcui="1306284">
<ATC code="V03AX03" />
<ATC code="J05AR09" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the quinidine due to decrease of its metabolism by the cobicistat</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DABIGATRAN" rxcui="1037042">
<ATC code="B01AE07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of dabigatran, with increase of the risk of bleeding</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>In a post surgical indication: clinical monitoring and adjustment of the dosage of the dabigatran to 150 mg/day in one dose.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DIGOXIN " rxcui="3407">
<ATC code="C01AA05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the digoxinemia due to decrease of the renal clearance of the digoxin. In addition, disorders of autoregulation (excessive bradycardia and disorders of atrioventricular conduction)</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and EKG. In the case of an unexpected result, test the digoxinemia and adjust the dosage. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DRONEDARONE" rxcui="233698">
<ATC code="C01BD07" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of bradycardia or of atrioventricular block, especially with older patients. Furthermore, slight increase of the concentrations of dronedarone due to decrease of its metabolism by the quinidine</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Start the treatment with quinidine at minimum recommended dosages, and adjust the doses according to the EKG. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="RITONAVIR BOOSTED PROTEASE INHIBITORS" code="J05AE-002" /></DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ITRACONAZOLE" rxcui="28031">
<ATC code="J02AC02" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes, as well as tinnitis and/or decrease of auditory acuity (cinchonism), due to decrease of the hepatic metabolism of the quinidine</DESCRIPTION>
<SEVERITY> CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="OMBITASVIR + PARITAPREVIR " code="OMPA" /></DRUG2>
<DESCRIPTION>Increase of the plasma concentrations of the quidinine due to decrease of its hepatic metabolism by the ombitasvir+paritaprevir combination</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="STIRIPENTOL" rxcui="37119">
<ATC code="N03AX17" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TAMOXIFEN" rxcui="10324">
<ATC code="L02BA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of reduction of the effectiveness of the tamoxifen, due to inhibition of the formation of its active metabolite by the quinidine</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TRICLABENDAZOLE" rxcui="38608">
<ATC code="P02BX04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes (inhibition of the hepatic metabolism of the torsade inducing medication)</DESCRIPTION>
<SEVERITY>CONTRAINDICATION </SEVERITY>
<COMMENT>Wait 24 hours between stopping the triclabendazole and the dose of the torsade inducing medication, and the reverse.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VERAPAMIL" rxcui="11170">
<ATC code="C08DA01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of large increase of the hemodynamic effects of the verapamil, with severe hypotension and bradycardia</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORICONAZOLE" rxcui="121243">
<ATC code="J02AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increased risk of ventricular arrhythmias, especially of torsades de pointes</DESCRIPTION>
<SEVERITY>CONTRAINDICATION</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>442-QUINIDINE.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="QUINIDINE" rxcui="9068">
<ATC code="C01BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="VORTIOXETINE" rxcui="1455099">
<ATC code="N06AX26" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the undesirable effects of the vortioxetine due to large decrease of its hepatic metabolism</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Clinical monitoring and possible adjustment of the dosage of the vortioxetine during the treatment with the quinidine and after it is stopped. </COMMENT>
</INTERACTION>
</INTERACTIONS>
